SENESCO TECHNOLOGIES – SNTI – #6
Senesco Technologies saw ups and downs over 2013, but we are banking on a big rise for the cancer therapeutics company. Senesco is sponsoring a Phase 1b/2a clinical trial of SNS01-T for patients with multiple myeloma who have relapsed from, or failed to respond to, at least two previous treatment regimens. This stock has some good upside in 2014.
52-Week High (02/08/13)